A closely watched clinical trial of Boston Scientific’s pulsed field ablation (PFA) device has met its primary endpoint. Boston Scientific published the data in The New England Journal of Medicine.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,